GlaxoSmithKline has entered an extensive collaboration with Jiangsu Hengrui Pharma to develop up to 12 novel medicines, including a PDE3/4 inhibitor targeting COPD, with upfront payments totaling $500 million and potential milestones up to $12 billion. Separately, Novatim Immune Therapeutics and ERIGEN have partnered to advance a dual-target BCMA/CD19 CAR-T therapy with global rights excluding Greater China. These deals underscore heightened biopharma innovation and deal-making momentum in Asia.